Search

Search Results

• ASSOCIATION BETWEEN HEPARIN DOSE AND 6-WEEKS MORTALITY IN PATIENTS WITH COVID-19

  Claire Coutureau, Philippe Nguyen, Maxime Hentzien, Peter Joe Noujaim, Sarah Zerbib, Damien Jolly, Lukshe Kanagaratnam

  e2022036

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.036

  820

  PDF: 485

  HTML: 364

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3699

  PDF: 1620

  HTML: 11532

  Figures Haase: 182

• THE FREQUENCY OF ADRENAL INSUFFICIENCY IN ADOLESCENTS AND YOUNG ADULTS WITH THALASSEMIA MAJOR VERSUS THALASSEMIA INTERMEDIA IN IRAN

  Sara Matin, Masoud Ghanei Jahromi, Zohreh Karemizadeh, Sezaneh Haghpanah, Vincenzo De Sanctis, Ashraf Soliman, Mehran Karimi

  e2015005

  2014-08-28

  https://doi.org/10.4084/mjhid.2015.005

  1987

  PDF: 1030

  HTML: 9535

• PREVALENCE AND MOLECULAR CHARACTERIZATION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY IN FEMALES FROM PREVIOUSLY MALARIA ENDEMIC REGIONS IN NORTHEASTERN THAILAND AND IDENTIFICATION OF A NOVEL G6PD VARIANT

  Sumalai Dechyotin, Kittipong Sakunthai, Noppmats Khemtonglang, Supawadee Yamsri, Kanokwan Sanchaisuriya, Kriengkrai Kitcharoen, Suttiphan Kitcharoen

  Page e2021029

  2021-04-30

  https://doi.org/10.4084/MJHID.2021.029

  1898

  PDF: 612

  HTML: 228

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4107

  PDF: 1426

  HTML: 583

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2028

  PDF: 1626

  HTML: 349

• CLINICAL FEATURES AND CLINICAL OUTCOME OF ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS TREATED AT CAIRO NATIONAL CANCER INSTITUTE IN EGYPT

  Ola Khorshid, Amira Diaa, Mohamed Abd El Moaty, Rafat Abd El Fatah, Ihab El Dessouk, Maha Abd El Hamid, Essam El Noshokaty, Ghada El Saied, Tamer M Fouad, Safaa M Ramadan

  e2011060

  2011-12-07

  https://doi.org/10.4084/mjhid.2011.060

  2986

  PDF: 915

  HTML: 2282

• IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.

  Jean Elcheikh

  e2013026

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.026

  1250

  PDF: 719

  HTML: 1391

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  2783

  PDF: 701

  HTML: 895

• ACUTE PROMYELOCYTIC LEUKEMIA: AN EXPERIENCE ON 95 GREEK PATIENTS TREATED IN THE ALL-TRANS-RETINOIC ACID ERA

  Maria Pagoni, Maria Garofalaki, Fotios Panitsas, Kalliopi Manola, Katerina Psarra, Panagiotis Economopoulos

  e2011053

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.053

  2786

  PDF: 846

  HTML: 3454

• Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

  Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

  e2010012

  2010-05-31

  https://doi.org/10.4084/mjhid.2010.012

  1023

  PDF: 677

  HTML: 334

• VIRAL HEPATITIS A TO E IN SOUTH MEDITERRANEAN COUNTRIES

  Sanaa M. Kamal, Sara Mahmoud, Tamer Hafez, Runia EL Fouly

  e2010001

  2010-02-09

  https://doi.org/10.4084/mjhid.2010.001

  1215

  PDF: 637

  HTML: 7717

• CLINICO-PATHOLOGICAL SPECTRUM AND NOVEL KARYOTYPIC FINDINGS IN MYELODYSPLASTIC SYNDROME: EXPERIENCE OF TERTIARY CARE CENTRE IN INDIA.

  Ruchi Gupta, Khaliqur Rahman, Manish Kumar Singh, Surabhi Kumari, Geeta yadav, Soniya Nityanand

  e2017048

  2017-08-16

  https://doi.org/10.4084/mjhid.2017.048

  1937

  PDF: 772

  HTML: 932

  Untitled: 194

• Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All Trans Retinoic Acid: A Monocentric Experience. Coagulopathy in APL treated with ATRA and Arsenic Trioxide.

  Francesco Autore, Patrizia Chiusolo, Federica Sora', Luca Laurenti, Livio Pagano, Andrea Bacigalupo, Valerio De Stefano, Simona Sica

  e2023009

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.009

  1037

  PDF: 1044

  HTML: 425

• VON WILLEBRAND FACTOR, ANGIODYSPLASIA AND ANGIOGENESIS

  Anna M. Randi, Mike A Laffan, Richard D. Starke

  e2013060

  2013-09-02

  https://doi.org/10.4084/mjhid.2013.060

  3692

  PDF: 1538

  HTML: 8013

  Randi Fig: 164

• Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA

  Bhavya S Doshi, Valder R Arruda, Valder R Arruda

  e2020069

  2020-09-08

  https://doi.org/10.4084/mjhid.2020.069

  1994

  PDF: 1833

  HTML: 335

• OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE

  Francesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, Miriam Isola, Maria Teresa Van Lint, Anna Paola Iori, Paolo Di Bartolomeo, Maurizio Musso, Pietro Pioltelli, Giuseppe Visani, Pasquale Iacopino, Renato Fanin, Alberto Bosi

  e2010010

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.010

  1471

  PDF: 754

  HTML: 756

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia

  Gabriele Magliano, Andrea Bacigalupo

  e2020081

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.081

  1523

  PDF: 489

  HTML: 150

• Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF

  Wen Yao, Xinchen Fang, Peng Jiang, Juan Tong, Liangquan Geng, Xiaoyu Zhu, Baolin Tang, Xiang Wan, Kaidi Song, Lei Zhang, Ping Qiang, Guangyu Sun, Yongsheng Han, Huilan Liu, Zimin Sun

  e2022025

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.025

  1726

  PDF: 551

  HTML: 269

• Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival

  Kenta Motegi

  e2026048

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.048

  100

  PDF: 99

  HTML: 10

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.

  Elisabetta Metafuni, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Sabrina Giammarco, Andrea Bacigalupo, Giuseppe Leone, Simona Sica

  e2018005

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.005

  4120

  PDF: 1041

  HTML: 1234

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2763

  PDF: 988

  HTML: 5506

• PERSISTENT COLONIC SCHISTOSOMIASIS AMONG SYMPTOMATIC RURAL INHABITANTS IN THE EGYPTIAN NILE DELTA Colonic schistosomiasis among rurals of the Egyptian Nile delta

  Mohamed Emara, Middle name: Hussien, Dr, Middle name: Asem, Dr, Prof., Prof., Dr.

  Page e2021033

  2021-04-29

  https://doi.org/10.4084/mjhid.2021.033

  1453

  PDF: 458

  MP4: 389

  Html: 182

• BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.

  Roberto Castelli

  e2016030

  2016-07-01

  https://doi.org/10.4084/mjhid.2016.030

  4299

  PDF: 959

  HTML: 1653

• MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA

  Alessandro Granito, Luigi Bolondi

  e2009021

  https://doi.org/10.4084/mjhid.2009.021

  711

  PDF: 455

  HTML: 6250

• CURRENT STRATEGIES FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

  Juliana Maria Camargos Rocha, Sandra Guerra Xavier, Marcelo Eduardo Lima Souza, Juliana Godoy Assumpção, Mitiko Murao, Benigna Maria Oliveira

  e2016024

  2016-04-10

  https://doi.org/10.4084/mjhid.2016.024

  4502

  PDF: 1304

  HTML: 4598

• VACCINATION FOLLOWING LEUKEMIA TREATMENT: VIRAL VACCINE RESPONSES IN SURVIVORS OF ACUTE LYMPHOBLASTIC LEUKEMIA

  Elif Kilic Konte, Ayca Koca Yozgat, Aysun Kara Uzun, Bahar Cuhaci Cakir, Nese Yarali

  e2025049

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.049

  766

  PDF: 520

  HTML: 21

• INFECTIOUS COMPLICATIONS AFTER UMBILICAL CORD-BLOOD TRANSPLANTATION FROM UNRELATED DONORS

  Juan Montoro, Jaime Sanz

  e2016051

  2016-10-18

  https://doi.org/10.4084/mjhid.2016.051

  3288

  PDF: 960

  HTML: 1436

• PATHOBIOLOGY OF HODGKIN LYMPHOMA

  Claudio Agostinelli, Stefano Pileri

  e2014040

  2014-06-05

  https://doi.org/10.4084/mjhid.2014.040

  3140

  PDF: 1391

  HTML: 5835

  Fig1-Ag-Pil: 206

  Ag-Pil Fig.2: 215

• ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS

  saveria capria, silvia maria trisolini, clara minotti, caterina stefanizzi, luisa cardarelli, Martina Canichella, claudio cartoni, daniela diverio, maria stefania de propris, marco mancini, alessandra micozzi, robin foà, giovanna meloni

  e2012072

  2012-11-06

  https://doi.org/10.4084/mjhid.2012.072

  1652

  PDF: 789

  HTML: 925

  cover letter: 253

• EBV IN HODGKIN LYMPHOMA

  Giuseppina Massini, Doerte Siemer, Stefan Hohaus

  e2009013

  https://doi.org/10.4084/mjhid.2009.013

  1624

  PDF: 583

  HTML: 13918

• The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study

  Sanaa Kamal, Moheyeldeen Mohamed Naghib, Jamaan Al Zahrani, Huda Hassan, Karim Abdel Aziz Moawado, Omar Arrahman

  e2021007

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.007

  2243

  PDF: 908

  HTML: 292

• Epidemiological surveillance of SARSCov2 in β-Thalassemia Patients in the last two years: reinfection rate, insights and future challenges

  Lorenza Torti, Francesco Sorrentino, Laura Maffei, Paolo De Fabritiis, Elisabetta Abruzzese

  e2023007

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.007

  857

  PDF: 906

  HTML: 388

• SOLITARY PLASMACYTOMA

  Sara Grammatico, Emilia Scalzulli, Maria Teresa Petrucci

  e2017052

  2017-08-23

  https://doi.org/10.4084/mjhid.2017.052

  3784

  PDF: 2144

  HTML: 1205

  fIGURES 1,2: 196

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

  Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani

  e2012069

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.069

  2466

  PDF: 690

  HTML: 1519

• PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM

  Richard A. Larson, Michelle Le Beau

  e2011032

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.032

  2763

  PDF: 894

  HTML: 1858

• ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

  Teresa L Field, Claudio Anasetti

  e2010019

  2010-07-19

  https://doi.org/10.4084/mjhid.2010.019

  1282

  PDF: 569

  HTML: 1178

• Acquired von Willebrand Syndrome associated to secondary IgM MGUS emerging after Autologous Stem Cell Transplantation for AL Amyloidosis

  Victor H Jimenez-Zepeda, Hina Qamar, Adrienne Lee, Karen Valentine, Leslie Skeith

  e2017034

  2017-05-01

  https://doi.org/10.4084/mjhid.2017.034

  2608

  PDF: 1012

  HTML: 1157

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  1973

  PDF: 743

  HTML: 3104

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1473

  PDF: 1304

  HTML: 108

• TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.

  Charicleia Kelaidi, Lionel Ades, Pierre Fenaux

  e2011038

  2011-09-08

  https://doi.org/10.4084/mjhid.2011.038

  2422

  PDF: 914

  HTML: 2320

• CHARACTERISTICS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA IN MULTI-TRANSFUSED PATIENTS WITH THALASSEMIA MAJOR. EXPERIENCE OF A SINGLE TERTIARY CENTER.

  Nikolaos Papadopoulos, Dimitrios Kountouras, Katerina Malagari, Maria Tampaki, Maria Theochari, John Koskinas

  e2020013

  2020-02-26

  https://doi.org/10.4084/mjhid.2020.013

  1687

  PDF: 935

  HTML: 209

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS

  Giuseppe Visani, Paola Picardi, Patrizia Tosi, Alessandro Isidori

  e2012075

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.075

  2486

  PDF: 848

  HTML: 2111

• THE IMPORTANCE OF EPIGENETIC ALTERATIONS IN THE DEVELOPMENT OF EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS

  Maria Takacs, Judit Segesdi, Ferenc Banati, Anita Koroknai, Hans Wolf, Hans Helmut Niller, Janos Minarovits

  e2009012

  https://doi.org/10.4084/mjhid.2009.012

  1017

  PDF: 506

  HTML: 2854

• Defining invasive fungal infection risk in hematological malignancies: a new tool for clinical practice

  Benedetta Rambaldi, Domenico Russo, Livio Pagano

  e2017012

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.012

  2577

  PDF: 1181

  HTML: 1555

• SEVERE LIVER IRON CONCENTRATIONS (LIC) IN 24 PATIENTS WITH ?-THALASSEMIA MAJOR: CORRELATIONS WITH SERUM FERRITIN, LIVER ENZYMES AND ENDOCRINE COMPLICATIONS

  Vincenzo De Sanctis

  e2018062

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.062

  2459

  PDF: 1318

  HTML: 291

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2091

  PDF: 709

  HTML: 1617

• DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA

  Sabina Chiaretti, Gina Zini, Renato Bassan

  e2014073

  2014-10-24

  https://doi.org/10.4084/mjhid.2014.073

  8943

  PDF: 5995

  HTML: 87916

  Fig.1b: 171

  Fig.1c: 171

  Fig.2a: 164

  Fig.2b: 163

  Fig.4: 175

  Fig.2c: 170

  Fig.3: 169

  Tab.1: 215

  Tab.2: 194

  Tab.3: 180

  Tab.4: 207

  Fig1a: 165

• Acquired CD20 Loss as a Mechanism of Resistance to Mosunetuzumab in Relapsed Follicular Lymphoma

  Martina Canichella, Stefano Fratoni, Carla Mazzone, alice di rocco, elisabetta abruzzese

  e2026014

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.014

  691

  PDF: 629

  Html: 121

• CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2024005

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.005

  1012

  PDF: 1315

  HTML: 94